Acurx Pharmaceuticals Inc (ACXP) 3.79 +0.16 (+4.41%)
3.79 +0.16 (+4.41%)
US00510M1045 - Common Stock
Acurx Pharmaceuticals Inc3.79
NASDAQ:ACXP (6/30/2022, 7:00:00 PM)+0.16 (+4.41%)
| GICS Sector | Health Care | ||
| GICS Industry | Biotechnology | ||
| Valuation | Growth | ||
| Profitability | Health | ||
| Dividend | |||
| Earnings (Last) | 05-10 2022-05-10/amc | Earnings (Next) | N/A N/A |
| Ins Owners | 22.72% | Inst Owners | 3.1% |
| Market Cap | 38.90M | Shares | 10.26M |
| PE | N/A | Fwd PE | N/A |
| Dividend Yield | N/A | Analysts | 82.86 |
| IPO | 06-25 2021-06-25 | ||
Stock Screener Links
Nasdaq Stock Screener
Find more stocks on Nasdaq
USA Stock Screener
Find more stocks on the USA
GICS Sector Stock Screener
Find competitors from the same sector on the USA
GICS Industry Stock Screener
Find competitors from the same industry on the USA
Technical Stock Screener
Find stocks with similar TA and Setup ratings on the USA
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Technical Competitors Stock Screener
Find the competitors with the best technical ratings on the USA
Best Technical Setups Competitors Stock Screener
Find the competitors with the best technical and setup ratings on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA
Best Analyst Rating Competitors Stock Screener
Find the competitors with the best analyst ratings on the USA
Company Profile
Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Staten Island, New York and currently employs 3 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in developing a class of antibiotics for infections caused by bacteria listed as pathogens by the World Health Organization (WHO), the United States Centers for Disease Control and Prevention, and the United States Food and Drug Administration (FDA). The firm develops antibiotic candidates that block the deoxyribonucleic acid (DNA) polymerase IIIC enzyme (Pol IIIC). Pol IIIC is the primary catalyst for DNA replication in Gram-positive bacterial cells. Its research and development pipeline include clinical-stage and early-stage antibiotic candidates that target Gram-positive bacteria for oral and/or parenteral treatment of infections caused by Clostridium difficile, Enterococcus, including vancomycin-resistant strains (VRE), Staphylococcus, including methicillin-resistant strains (MRSA) and Streptococcus, including antibiotic resistant strains.
Company Info
Acurx Pharmaceuticals Inc
259 Liberty Avenue
Staten Island NEW YORK
P: 19175331469.0
CEO: David P. Luci
Employees: 3
Website: https://www.acurxpharma.com/
ACXP Twits
Here you can normally see the latest stock twits on ACXP, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
